News releases Year None 2026 2025 2024 2023 2022 2021 2019 Oct 28, 2026 Pyxis Oncology to Participate in Upcoming Investor Conferences PDF Version Oct 27, 2026 Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics PDF Version Oct 02, 2026 Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering PDF Version Sep 30, 2026 Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering PDF Version Sep 29, 2026 Pyxis Oncology Announces Proposed Public Offering PDF Version Sep 09, 2026 Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) PDF Version Sep 08, 2026 Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) PDF Version Sep 08, 2026 Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board PDF Version Sep 01, 2026 Pyxis Oncology to Participate in Upcoming Investor Conferences PDF Version Aug 13, 2026 Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones PDF Version Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 17
Year None 2026 2025 2024 2023 2022 2021 2019 Oct 28, 2026 Pyxis Oncology to Participate in Upcoming Investor Conferences PDF Version Oct 27, 2026 Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics PDF Version Oct 02, 2026 Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering PDF Version Sep 30, 2026 Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering PDF Version Sep 29, 2026 Pyxis Oncology Announces Proposed Public Offering PDF Version Sep 09, 2026 Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) PDF Version Sep 08, 2026 Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) PDF Version Sep 08, 2026 Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board PDF Version Sep 01, 2026 Pyxis Oncology to Participate in Upcoming Investor Conferences PDF Version Aug 13, 2026 Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones PDF Version Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 17
